Protagenic Therapeutics Inc Stock Price, News & Analysis

Protagenic Therapeutics (NASDAQ:PTIX) announced completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study of lead peptide PT00114 in healthy volunteers on November 13, 2025. The trial evaluated safety and tolerability after multiple doses. The company said it will deliver a full summation of safety analysis by the end of the month and expects to release top-line MAD results by November 30, 2025. Protagenic noted it previously completed a single ascending dose study in early 2025 and described PT00114 as a first-in-class candidate targeting resilience to chronic stress and related neurological effects.

Protagenic Therapeutics (Nasdaq:PTIX), a biopharmaceutical company, announced a delay in filing its Q2 2025 Form 10-Q due to ongoing merger-related financial consolidation work. The company received a Nasdaq notice on August 20, 2025 regarding non-compliance with Listing Rule 5250(c)(1).

The delay is attributed to the need to complete merger-related financial consolidation, including purchase accounting adjustments and pro forma financial information. While PTIX's securities continue trading on Nasdaq Capital Market, the company plans to regain compliance promptly upon filing and will submit a compliance plan if necessary.

Protagenic Therapeutics (NASDAQ:PTIX) has announced significant progress in the clinical development of PT00114, its novel neuro-active peptide therapy. The company has completed first dose injection for all subjects in the multiple-dose portion of its Phase 1 trial, with full dosing completion expected by August end 2025.

PT00114 is pioneering as the first investigational therapy based on Teneurin C-terminus Associated Peptide (TCAP), a natural brain hormone that regulates stress and emotional balance. The drug targets the amygdala and hippocampus, offering a differentiated approach to treating anxiety, depression, addiction, and PTSD.

Following successful completion of a single ascending dose trial demonstrating favorable safety, the company anticipates topline safety data by September 2025 and plans to advance to Phase 2 efficacy studies in Q1 2026.

Protagenic Therapeutics (Nasdaq: PTIX) has secured a new Japanese patent (JP 7714571B) for its modified stilbenoid program drug candidates, valid until March 31, 2041. The patent covers compounds, formulations, and medical applications specifically targeting epilepsy and seizure treatments.

This development follows the previous grant of the same patent in the UK (Patent GB2609814). The company plans to pursue patent protection in additional territories to strengthen its development pipeline and intellectual property portfolio.

PROG Holdings (NYSE:PRG) has reported that warrant exchanges and exercises over the past four trading days have generated $3.1 million in cash proceeds. The company plans to use these funds for working capital needs and to advance its development of peptide-based drug candidates targeting stress-related and central nervous system disorders.

The financing coincides with Protagenic's recently announced business combination with Phytanix Bio Inc. (May 19, 2025), which has consolidated six complementary drug development programs focusing on stress disorders, epilepsy, obesity, and other indications under one organization.

Protagenic Therapeutics (NASDAQ: PTIX) has secured $3.1 million in funding through warrant exchanges and exercises over a four-day trading period. The company plans to utilize these proceeds for working capital requirements and to advance its development of peptide-based drug candidates targeting stress-related and central nervous system disorders. This financial development follows Protagenic's recently announced business combination with Phytanix Bio Inc. on May 19, 2025, which has consolidated six complementary drug development programs focusing on stress disorders, epilepsy, obesity, and other indications under a single entity.

Protagenic Therapeutics (NASDAQ: PTIX) and Phytanix Bio have agreed to merge in an all-stock transaction to form Phytanix, Inc., creating a neuroactive biopharmaceutical company. The combined entity will feature six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The merger structure results in Phytanix Bio stockholders owning approximately 65% of the combined company, while pre-merger Protagenic shareholders will retain about 35%. The transaction includes the issuance of common stock, convertible preferred stock, and warrants, subject to Nasdaq stockholder approval requirements.

Protagenic Therapeutics has announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025. This strategic move aims to maintain Nasdaq compliance with minimum bid price requirements.

The split will reduce outstanding shares from approximately 8.2 million to 588,750. Trading will continue under the symbol PTIX with a new CUSIP number (74365N301). Key points include:

• Stockholder approval received on April 18, 2025, for a ratio range of 1-for-10 to 1-for-20
• Automatic conversion: 14 current shares will convert to 1 new share
• Fractional shares will be rounded up to the next whole share
• Proportionate adjustments will apply to exercise prices and equity awards

Equiniti Trust Company, the transfer agent, will handle the conversion process. Book-entry holders require no action, while certificate holders will receive instructions via mail for share conversion.

Protagenic Therapeutics (NASDAQ:PTIX) has closed a private placement raising $1.275 million in gross proceeds. The offering included 1,948,295 shares of common stock and two series of warrants. Each series includes 1,948,295 warrants with an exercise price of $0.64 per share. Series A warrants have an 18-month term, while Series B warrants extend for 5 years. The purchase price was set at $0.64 per share ($0.89 for insiders). The company plans to use the proceeds for working capital purposes. Brookline Capital Markets acted as the sole placement agent.